YOUNG WILLIAM D 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Jan 6, 2020
Insider Transaction Report
Form 4
YOUNG WILLIAM D
Director
Transactions
- Exercise/Conversion
Common Stock
2020-01-02$72.14/sh+20,000$1,442,800→ 29,311 total - Sale
Common Stock
2020-01-02$217.72/sh−2,500$544,300→ 26,811 total - Sale
Common Stock
2020-01-02$218.73/sh−7,266$1,589,292→ 19,545 total - Sale
Common Stock
2020-01-02$219.37/sh−10,134$2,223,096→ 9,411 total - Sale
Common Stock
2020-01-02$220.08/sh−100$22,008→ 9,311 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-02−20,000→ 0 totalExercise: $72.14Exp: 2024-05-31→ Common Stock (20,000 underlying)
Footnotes (6)
- [F1]Transaction made pursuant to Mr. Young's company approved trading plan under Rule 10b5-1.
- [F2]Open market sales reported on this line occurred at a weighted average price of $217.72 (range $217.08 to $218.06).
- [F3]Mr. Young undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Open market sales reported on this line occurred at a weighted average price of $218.73 (range $218.08 to $219.07).
- [F5]Open market sales reported on this line occurred at a weighted average price of $219.37 (range $219.08 to $219.78).
- [F6]Fully vested.